Gaëtane Le Toumelin-Braizat

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

Medicine, Oncology, Pharmacology +11

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Patrick Casara, James Davidson, Audrey Clapéron et al. · Oncotarget · 2018 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Zoltán Szlávik, Márton Csékei, Attila Paczal et al. · Journal of Medicinal Chemistry · 2020 · 106 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Patrick Casara, James Davidson, Audrey Clapéron et al. · HAL (Le Centre pour la Communication Scientifique Directe) · 2018 · 48 citations

Medicine, Oncology, Pharmacology +17

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Ana Leticia Maragno, Prakash Mistry, András Kotschy et al. · Cancer Research · 2019 · 13 citations

Medicine, Oncology, Pharmacology +17